Addiction - Pipeline Review, H1 2015

Published: Mar, 2015 | Pages: 287 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Addiction - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Addiction - Pipeline Review, H1 2015’, provides an overview of the Addiction’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Addiction and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Addiction
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Addiction and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Addiction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Addiction pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Addiction
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Addiction pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Addiction Overview 11
Therapeutics Development 12
Pipeline Products for Addiction - Overview 12
Pipeline Products for Addiction - Comparative Analysis 13
Addiction - Therapeutics under Development by Companies 14
Addiction - Therapeutics under Investigation by Universities/Institutes 20
Addiction - Pipeline Products Glance 22
Late Stage Products 22
Clinical Stage Products 23
Early Stage Products 24
Unknown Stage Products 25
Addiction - Products under Development by Companies 26
Addiction - Products under Investigation by Universities/Institutes 33
Addiction - Companies Involved in Therapeutics Development 35
AbbVie Inc. 35
Acura Pharmaceuticals, Inc. 36
Addex Therapeutics Ltd 37
Adial Pharmaceuticals, LLC 38
Alkermes Plc 39
Aphios Corporation 40
Aradigm Corporation 41
Arena Pharmaceuticals, Inc. 42
Astraea Therapeutics, LLC 43
AstraZeneca PLC 44
Beech Tree Labs, Inc. 45
BioDelivery Sciences International, Inc. 46
Bionex Pharmaceuticals LLC 47
Bioprojet SCR 48
Camurus AB 49
Celtic Pharmaceutical Holdings L.P. 50
Cerecor Inc. 51
Curemark, LLC 52
D&A Pharma SAS 53
Eli Lilly and Company 54
Embera NeuroTherapeutics, Inc. 55
Euthymics Bioscience, Inc. 56
Foresee Pharmaceuticals, LLC 57
FORUM Pharmaceuticals Inc. 58
Gilead Sciences, Inc. 59
GlaxoSmithKline plc 60
Grunenthal GmbH 61
Heptares Therapeutics Ltd. 62
Immunovaccine, Inc. 63
Indivior PLC 64
INSYS Therapeutics, Inc. 65
Invion Limited 66
Johnson & Johnson 67
Kyorin Pharmaceutical Co., Ltd. 68
Lightlake Therapeutics Inc. 69
Lohocla Research Corporation 70
MAKScientific, LLC 71
NAL Pharmaceuticals Ltd. 72
Nanotherapeutics, Inc. 73
Omeros Corporation 74
Pfizer Inc. 75
Relmada Therapeutics, Inc. 76
Rottapharm SpA 77
Royalty Pharma 78
Selecta Biosciences, Inc. 79
SK Biopharmaceuticals Co., Ltd. 80
Sun Pharma Advanced Research Company Ltd. 81
Targacept, Inc. 82
Tekmira Pharmaceuticals Corp. 83
Teva Pharmaceutical Industries Limited 84
Titan Pharmaceuticals, Inc. 85
Tonix Pharmaceuticals Holding Corp. 86
VM Discovery, Inc. 87
Zynerba Pharmaceuticals, Inc. 88
Addiction - Therapeutics Assessment 89
Assessment by Monotherapy Products 89
Assessment by Combination Products 90
Assessment by Target 91
Assessment by Mechanism of Action 94
Assessment by Route of Administration 97
Assessment by Molecule Type 99
Drug Profiles 101
(buprenorphine hydrochloride + naloxone hydrochloride) - Drug Profile 101
(buprenorphine hydrochloride + naloxone hydrochloride) - Drug Profile 102
(disulfiram + selegiline) - Drug Profile 103
(oxazepam + metyrapone) - Drug Profile 104
(topiramate + ondansetron hydrochloride) - Drug Profile 106
ABT-436 - Drug Profile 107
ADX-71441 - Drug Profile 108
ADX-88178 - Drug Profile 109
AM-6527 - Drug Profile 110
amitifadine - Drug Profile 112
Anatabine - Drug Profile 114
Antisense Gene Therapy to Inhibit Aldehyde Dehydrogenase for Alcoholism - Drug Profile 115
arbaclofen placarbil - Drug Profile 116
ARD-1600 - Drug Profile 118
ASB - Drug Profile 119
AT-1001 - Drug Profile 120
baclofen ER - Drug Profile 121
BP-1.4979 - Drug Profile 122
BTL-ng - Drug Profile 123
Buprenorphine Hemiadipate Hydrochloride - Drug Profile 124
buprenorphine hydrochloride - Drug Profile 125
buprenorphine hydrochloride - Drug Profile 126
buprenorphine hydrochloride - Drug Profile 127
buprenorphine hydrochloride depot - Drug Profile 130
buprenorphine hydrochloride ER - Drug Profile 131
buprenorphine hydrochloride SR - Drug Profile 132
cannabidiol - Drug Profile 134
cannabidiol - Drug Profile 135
cannabidiol - Drug Profile 137
carisbamate - Drug Profile 138
CM-1212 - Drug Profile 140
CR-5542 Series - Drug Profile 141
CR-5772 Series - Drug Profile 142
dipraglurant IR - Drug Profile 143
dronabinol - Drug Profile 144
Drug for Dependence - Drug Profile 145
Drug to Inhibit Triple Reuptake for Alcohol Dependence - Drug Profile 146
Drugs to Activate HAT for CNS Disorders - Drug Profile 147
Drugs to Inhibit FAAH for CNS Disorders - Drug Profile 148
Drugs to Inhibit Histone Deacetylase for CNS Disorders - Drug Profile 149
Drugs to Target HAT and HDAC for Alcohol Addiction and Anxiety Disorders - Drug Profile 150
encenicline hydrochloride - Drug Profile 151
FP-004 - Drug Profile 154
FP-007 - Drug Profile 155
GET-73 - Drug Profile 156
GS-6637 - Drug Profile 157
GSK-598809 - Drug Profile 158
ibudilast - Drug Profile 159
JNJ-31020028 - Drug Profile 161
JNJ-5234801 - Drug Profile 162
lorcaserin hydrochloride - Drug Profile 163
LT-22 - Drug Profile 166
LY-2456302 - Drug Profile 167
LY-2940094 - Drug Profile 168
MAL - Drug Profile 169
methadone IR - Drug Profile 170
methoxycoronaridine - Drug Profile 171
nadolol - Drug Profile 172
naltrexone - Drug Profile 174
naltrexone - Drug Profile 175
NIC7-DT - Drug Profile 176
nicotine - Drug Profile 177
nicotine - Drug Profile 178
Nicotine Vaccine - Drug Profile 179
NOX-B11 - Drug Profile 180
odelepran hydrochloride - Drug Profile 181
OMS-405 - Drug Profile 182
OMS-527 - Drug Profile 183
ondansetron hydrochloride - Drug Profile 185
PF-04457845 - Drug Profile 186
PF-05402536 - Drug Profile 187
PF-06413367 - Drug Profile 188
PF-5006739 - Drug Profile 189
phantasmidine - Drug Profile 190
RO-656570 - Drug Profile 191
samidorphan - Drug Profile 192
saracatinib difumarate - Drug Profile 193
SEL-068 - Drug Profile 195
SLV-330 - Drug Profile 197
Small Molecule for Central Nervous System - Drug Profile 198
Small Molecule for Drug Addiction - Drug Profile 200
Small Molecule for Smoking Cessation - Drug Profile 201
Small Molecule for Smoking Cessation and Appetite Suppression - Drug Profile 202
Small Molecule to Activate Kappa Opioid Receptor for CNS - Drug Profile 203
Small Molecule to Agonize Alpha 4Beta 2 and Alpha 6Beta 2 Neuronal Nicotinic Receptor for Smoking Cessation - Drug Profile 204
Small Molecule to Agonize Neuronal Nicotinic Acetylcholine Receptor for Smoking Cessation - Drug Profile 205
Small Molecule to Antagonize Ghrelin for Alcoholism - Drug Profile 206
Small Molecule to Antagonize Mu Opioid Receptor for Drug Abuse and Alcohol Addiction - Drug Profile 207
Small Molecule to Antagonize Orexin 1 for Addiction and Compulsive Disorders - Drug Profile 208
Small Molecule to Inhibit BRD for Cocaine Dependence - Drug Profile 209
Small Molecule to Inhibit Kappa Opioid Receptor for CNS - Drug Profile 210
Small Molecules to Activate Delta Opioid Receptor for Immunology, CNS and Metabolic Disorders - Drug Profile 211
Small Molecules to Agonize Alpha 4 Neuronal Nicotinic Receptor for Smoking Cessation - Drug Profile 212
Small Molecules to Agonize NOP for Pain and Alcohol Addiction - Drug Profile 213
Small Molecules to Inhibit CB1 Receptor for Cannabinoid Abuse and Drug Addiction - Drug Profile 214
Small Molecules to Inhibit DAT and SERT for CNS Disorders - Drug Profile 215
Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders - Drug Profile 216
Small Molecules to Inhibit Nicotinic Acetylcholine Receptor for Smoking Cessation - Drug Profile 217
Small Molecules to Inhibit NTR1 for Psychiatric Disorders - Drug Profile 218
Small Molecules to Modulate 5HT2 for CNS and Metabolic Disorders - Drug Profile 219
sodium oxybate IR - Drug Profile 220
Synthetic Peptides to Inhibit Mu Opioid, Delta Opioid and MRP-1 for Oncology and Morphine Addiction - Drug Profile 221
Synthetic Peptides to Target DOR, MOR and MRP-1 for Oncology and CNS Disorders - Drug Profile 222
TA-CD - Drug Profile 223
TKM-ALDH2 - Drug Profile 224
TV-1380 - Drug Profile 225
Vaccine for Cocaine Addiction - Drug Profile 226
Vaccine for Cocaine Addiction - Drug Profile 227
Vaccine for Methamphetamine Addiction - Drug Profile 228
Vaccine for Nicotine Addiction - Drug Profile 229
Vaccine for Nicotine Addiction - Drug Profile 230
Vaccine for Opium Addiction - Drug Profile 231
VMD-2202 - Drug Profile 232
Addiction - Recent Pipeline Updates 233
Addiction - Dormant Projects 261
Addiction - Discontinued Products 268
Addiction - Product Development Milestones 270
Featured News & Press Releases 270
Appendix 278
Methodology 278
Coverage 278
Secondary Research 278
Primary Research 278
Expert Panel Validation 278
Contact Us 278
Disclaimer 279

List of Tables

Number of Products under Development for Addiction, H1 2015 20
Number of Products under Development for Addiction - Comparative Analysis, H1 2015 21
Number of Products under Development by Companies, H1 2015 23
Number of Products under Development by Companies, H1 2015 (Contd..1) 24
Number of Products under Development by Companies, H1 2015 (Contd..2) 25
Number of Products under Development by Companies, H1 2015 (Contd..3) 26
Number of Products under Development by Companies, H1 2015 (Contd..4) 27
Number of Products under Investigation by Universities/Institutes, H1 2015 29
Comparative Analysis by Late Stage Development, H1 2015 30
Comparative Analysis by Clinical Stage Development, H1 2015 31
Comparative Analysis by Early Stage Development, H1 2015 32
Comparative Analysis by Unknown Stage Development, H1 2015 33
Products under Development by Companies, H1 2015 34
Products under Development by Companies, H1 2015 (Contd..1) 35
Products under Development by Companies, H1 2015 (Contd..2) 36
Products under Development by Companies, H1 2015 (Contd..3) 37
Products under Development by Companies, H1 2015 (Contd..4) 38
Products under Development by Companies, H1 2015 (Contd..5) 39
Products under Development by Companies, H1 2015 (Contd..6) 40
Products under Investigation by Universities/Institutes, H1 2015 41
Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 42
Addiction - Pipeline by AbbVie Inc., H1 2015 43
Addiction - Pipeline by Acura Pharmaceuticals, Inc., H1 2015 44
Addiction - Pipeline by Addex Therapeutics Ltd, H1 2015 45
Addiction - Pipeline by Adial Pharmaceuticals, LLC, H1 2015 46
Addiction - Pipeline by Alkermes Plc, H1 2015 47
Addiction - Pipeline by Aphios Corporation, H1 2015 48
Addiction - Pipeline by Aradigm Corporation, H1 2015 49
Addiction - Pipeline by Arena Pharmaceuticals, Inc., H1 2015 50
Addiction - Pipeline by Astraea Therapeutics, LLC, H1 2015 51
Addiction - Pipeline by AstraZeneca PLC, H1 2015 52
Addiction - Pipeline by Beech Tree Labs, Inc., H1 2015 53
Addiction - Pipeline by BioDelivery Sciences International, Inc., H1 2015 54
Addiction - Pipeline by Bionex Pharmaceuticals LLC, H1 2015 55
Addiction - Pipeline by Bioprojet SCR, H1 2015 56
Addiction - Pipeline by Camurus AB, H1 2015 57
Addiction - Pipeline by Celtic Pharmaceutical Holdings L.P., H1 2015 58
Addiction - Pipeline by Cerecor Inc., H1 2015 59
Addiction - Pipeline by Curemark, LLC, H1 2015 60
Addiction - Pipeline by D&A Pharma SAS, H1 2015 61
Addiction - Pipeline by Eli Lilly and Company, H1 2015 62
Addiction - Pipeline by Embera NeuroTherapeutics, Inc., H1 2015 63
Addiction - Pipeline by Euthymics Bioscience, Inc., H1 2015 64
Addiction - Pipeline by Foresee Pharmaceuticals, LLC, H1 2015 65
Addiction - Pipeline by FORUM Pharmaceuticals Inc., H1 2015 66
Addiction - Pipeline by Gilead Sciences, Inc., H1 2015 67
Addiction - Pipeline by GlaxoSmithKline plc, H1 2015 68
Addiction - Pipeline by Grunenthal GmbH, H1 2015 69
Addiction - Pipeline by Heptares Therapeutics Ltd., H1 2015 70
Addiction - Pipeline by Immunovaccine, Inc., H1 2015 71
Addiction - Pipeline by Indivior PLC, H1 2015 72
Addiction - Pipeline by INSYS Therapeutics, Inc., H1 2015 73
Addiction - Pipeline by Invion Limited, H1 2015 74
Addiction - Pipeline by Johnson & Johnson, H1 2015 75
Addiction - Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2015 76
Addiction - Pipeline by Lightlake Therapeutics Inc., H1 2015 77
Addiction - Pipeline by Lohocla Research Corporation, H1 2015 78
Addiction - Pipeline by MAKScientific, LLC, H1 2015 79
Addiction - Pipeline by NAL Pharmaceuticals Ltd., H1 2015 80
Addiction - Pipeline by Nanotherapeutics, Inc., H1 2015 81
Addiction - Pipeline by Omeros Corporation, H1 2015 82
Addiction - Pipeline by Pfizer Inc., H1 2015 83
Addiction - Pipeline by Relmada Therapeutics, Inc., H1 2015 84
Addiction - Pipeline by Rottapharm SpA, H1 2015 85
Addiction - Pipeline by Royalty Pharma, H1 2015 86
Addiction - Pipeline by Selecta Biosciences, Inc., H1 2015 87
Addiction - Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2015 88
Addiction - Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2015 89
Addiction - Pipeline by Targacept, Inc., H1 2015 90
Addiction - Pipeline by Tekmira Pharmaceuticals Corp., H1 2015 91
Addiction - Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 92
Addiction - Pipeline by Titan Pharmaceuticals, Inc., H1 2015 93
Addiction - Pipeline by Tonix Pharmaceuticals Holding Corp., H1 2015 94
Addiction - Pipeline by VM Discovery, Inc., H1 2015 95
Addiction - Pipeline by Zynerba Pharmaceuticals, Inc., H1 2015 96
Assessment by Monotherapy Products, H1 2015 97
Assessment by Combination Products, H1 2015 98
Number of Products by Stage and Target, H1 2015 100
Number of Products by Stage and Mechanism of Action, H1 2015 103
Number of Products by Stage and Route of Administration, H1 2015 106
Number of Products by Stage and Molecule Type, H1 2015 108
Addiction Therapeutics - Recent Pipeline Updates, H1 2015 241
Addiction - Dormant Projects, H1 2015 269
Addiction - Dormant Projects (Contd..1), H1 2015 270
Addiction - Dormant Projects (Contd..2), H1 2015 271
Addiction - Dormant Projects (Contd..3), H1 2015 272
Addiction - Dormant Projects (Contd..4), H1 2015 273
Addiction - Dormant Projects (Contd..5), H1 2015 274
Addiction - Dormant Projects (Contd..6), H1 2015 275
Addiction - Discontinued Products, H1 2015 276
Addiction - Discontinued Products (Contd..1), H1 2015 277